Aurora Private Wealth Inc. cut its stake in Johnson & Johnson (NYSE:JNJ) by 37.8% during the 2nd quarter, HoldingsChannel reports. The fund owned 11,032 shares of the company’s stock after selling 6,713 shares during the period. Johnson & Johnson comprises 0.7% of Aurora Private Wealth Inc.’s portfolio, making the stock its 23rd largest position. Aurora Private Wealth Inc.’s holdings in Johnson & Johnson were worth $1,551,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Canton Hathaway LLC increased its holdings in Johnson & Johnson by 2.7% in the second quarter. Canton Hathaway LLC now owns 7,594 shares of the company’s stock valued at $1,068,000 after buying an additional 200 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its position in shares of Johnson & Johnson by 2.6% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 502,899 shares of the company’s stock worth $70,723,000 after acquiring an additional 12,692 shares in the last quarter. Baldwin Investment Management LLC increased its holdings in shares of Johnson & Johnson by 2.0% in the 2nd quarter. Baldwin Investment Management LLC now owns 10,286 shares of the company’s stock valued at $1,447,000 after acquiring an additional 200 shares during the last quarter. Lindbrook Capital LLC raised its position in shares of Johnson & Johnson by 6.2% during the 2nd quarter. Lindbrook Capital LLC now owns 4,269 shares of the company’s stock valued at $600,000 after acquiring an additional 250 shares in the last quarter. Finally, Cornerstone Wealth Group LLC raised its position in shares of Johnson & Johnson by 2.3% during the 2nd quarter. Cornerstone Wealth Group LLC now owns 23,544 shares of the company’s stock valued at $3,311,000 after acquiring an additional 539 shares in the last quarter. Hedge funds and other institutional investors own 68.44% of the company’s stock.
Shares of Johnson & Johnson stock opened at $145.76 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 1.05. Johnson & Johnson has a 1-year low of $109.16 and a 1-year high of $157.00. The business’s fifty day moving average price is $144.04 and its two-hundred day moving average price is $144.14. The company has a market capitalization of $386.60 billion, a P/E ratio of 21.31, a PEG ratio of 3.25 and a beta of 0.69.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.17. The business had revenue of $18.34 billion for the quarter, compared to analysts’ expectations of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The company’s revenue was down 10.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.58 earnings per share. On average, research analysts expect that Johnson & Johnson will post 7.85 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a dividend of $1.01 per share. The ex-dividend date is Monday, August 24th. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.77%. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.
Several research firms have weighed in on JNJ. ValuEngine lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, July 15th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $160.00 to $170.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Credit Suisse Group reiterated a “buy” rating and set a $161.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Raymond James lifted their target price on Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Finally, Zacks Investment Research downgraded Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price target on the stock. in a report on Tuesday, July 7th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $163.38.
In other news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the transaction, the executive vice president now directly owns 21,682 shares in the company, valued at $3,197,444.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.27% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What is the cash asset ratio?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.